Non-Replicating Bovine Leukemia Virus Vaccine with pol Gene Deletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for bovine leukemia virus (BLV) are ineffective due to the low viral production levels and the risk of integration into the host genome, making it difficult to develop safe and effective immunization strategies.
Innovation Solution
Development of a non-replicating BLV with a deficient pol gene, specifically lacking reverse transcriptase and integrase function, which is produced by a modified cell line, allowing for increased viral expression and immunogenicity without replication in infected subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BLV is used to develop a vaccine, then immunogenicity is improved, but the risk of viral integration into host genome increases
Solution Approach 1:
The patent extracts and removes the pol gene (encoding reverse transcriptase and integrase) from the BLV genome to create a replication-defective virus. This extraction eliminates the harmful integration function while preserving the immunogenic antigens, resolving the contradiction between vaccine effectiveness and safety.
Solution Approach 2:
The patent changes the genetic parameters of BLV by deleting the pol gene region, transforming it from a replication-competent virus to a replication-defective virus. This parameter change maintains immunogenicity while eliminating the ability to integrate into host DNA.
2Quantity of substance
If BLV production from infected cells is increased, then vaccine dosage is improved, but the risk of replication and integration increases
Solution Approach 1:
The patent converts the harmful replication capability of BLV into a benefit by using the same cellular machinery to produce large amounts of replication-defective virus particles. The deleted pol gene prevents replication while allowing high-level production of immunogenic virus particles for vaccination.
3Productivity
If expression vectors are used to increase BLV production, then vaccine quantity is improved, but the complexity of the system increases
Solution Approach 1:
The patent merges the vaccine production function directly into the virus itself by deleting the pol gene, eliminating the need for separate expression vectors and complex transfection systems. The replication-defective BLV can be produced through simple transfection of packaging cells, greatly simplifying the manufacturing process.
Data Source
AI summary
An object of the present invention is to provide a novel non-replicating bovine leukemia virus (BLV) and a producing cell thereof. According to the present invention, there is provided a bovine leukemia virus (BLV) in which at least a part of the function of a pol gene is deficient. Also, according to the present invention, there is provided a non-replicating BLV-producing cell comprising a gene of a BLV in which at least a part of the function of a pol gene is deficient. The present invention is advantageous in that it can provide a BLV vaccine which is highly immunogenic, and is highly safe without replicating in an infected subject.